SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 88.66 |
| Enterprise Value ($M) | 46.37 |
| Book Value ($M) | 137.46 |
| Book Value / Share | 4.22 |
| Price / Book | 0.65 |
| NCAV ($M) | 109.59 |
| NCAV / Share | 3.36 |
| Price / NCAV | 0.81 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.56 |
| Return on Assets (ROA) | -0.61 |
| Return on Equity (ROE) | -0.80 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 8.47 |
| Current Ratio | 8.47 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 142.37 |
| Assets | 170.23 |
| Liabilities | 32.78 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Janus Henderson Group Plc | 7.20 | ||
| 13G/A | Viking Global Investors Lp | 4.50 | 0.00 | |
| 13G/A | Qatar Investment Authority | 3.82 | 0.00 | |
| 13G | Suvretta Capital Management, Llc | 5.10 | ||
| 13G | Oxford Science Enterprises plc | 14.70 | ||
| 13D/A | Ra Capital Management, L.p. | 33.10 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 27,503 | 98,757 | 27.85 | |
| 13,427 | 122,419 | 10.97 | |
| 11,784 | 229,666 | 5.13 | |
| 8,356 | 153,593 | 5.44 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PBYI – Puma Biotechnology, Inc. | PCRX – Pacira BioSciences, Inc. |
| PCVX – Vaxcyte, Inc. | PGEN – Precigen, Inc. |
| PHAT – Phathom Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io